Cat. No. | Product name | CAS No. |
DC8468 |
AZD-6738
Featured
AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2. |
1352226-88-0 |
DC7076 |
AZD-7762
Featured
AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM; equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. |
860352-01-8 |
DC5084 |
AZD-8055
Featured
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. |
1009298-09-2 |
DC8380 |
AZD8186
Featured
AZD8186 is an inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. |
1627494-13-6 |
DC7077 |
AZD8330(ARRY-424704; ARRY-704)
Featured
AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. |
869357-68-6 |
DC9879 |
AZD8835
Featured
AZD8835 ia a novel mixed inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity against PI3Kβ (IC50=431 nM) and PI3Kγ (IC50=90 nM). |
1620576-64-8 |
DC7006 |
AZD-9291(Osimertinib)
Featured
AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
1421373-65-0 |
DC8462 |
AZD-9291 mesylate (Osimertinib,Mereletinib)
Featured
AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM). |
1421373-66-1 |
DC9268 |
AZD9496
Featured
AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator(Ki=0.7 nM) and antagonist. |
1639042-08-2 |
DC2013 |
Bafetinib (INNO-406)
Featured
Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM and 19 nM, respectively. |
859212-16-1 |
DC9939 |
BAY 1082439
BAY 1082439 is a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN. |
1375469-38-7 |
DC10376 |
BAY-1143572
BAY 1143572 is a highly selective, potent and orally available inhibitor of PTEFb/CDK9; inhibits the proliferation of AML cell lines with a median IC50 of 385 nM. |
1414943-88-6 |
DC10408 |
BAY1125976
Featured
BAY1125976 is a selective allosteric Akt1/2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively. |
1402608-02-9 |
DC9679 |
BAY1217389
Featured
BAY1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. |
1554458-53-5 |
DC11719 |
BAY-1436032
BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively. |
1803274-65-8 |
DC10526 |
BAY-1895344 HCl(Elimusertib)
Featured
BAY-1895344 is a potent and selective ATM inhibitor. BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride. |
1876467-74-1 |
DC10448 |
Belizatinib(TSR-011)
Featured
Belizatinib(TSR-011) is an orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. |
1357920-84-3 |
DC9832 |
Betulinic acid
Featured
Betulinic acid, a pentacyclic triterpene, selectively induces apoptosis in tumor cells, also is a inhibitor of HIV-1 with EC50 of 1.4 μ M. |
472-15-1 |
DC3136 |
NVP-BEZ235
Featured
BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor of p110α, p110γ, p110δ and p110β with IC50 of 4 nM, 5 nM, 7 nM and 75 nM, respectively, and also inhibits ATR with IC50 of 21 nM. |
915019-65-7 |
DC10335 |
BGB-3111
BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. |
1633350-06-7 |
DC5194 |
NVP-BGJ398(Infigratinib)
Featured
BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2. |
872511-34-7 |
DC7083 |
Bi 2536
Featured
BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM, BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3; BI2536 also is a BRD4 inhibitor(IC50= 25 nM). |
755038-02-9 |